UBS Upgrades Teva Pharmaceutical Indus to Neutral, Raises Price Target to $8
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Ashwani Verma has upgraded Teva Pharmaceutical Indus (NYSE:TEVA) from Sell to Neutral and raised the price target from $7 to $8.
July 06, 2023 | 10:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Teva Pharmaceutical Indus has been upgraded from Sell to Neutral by UBS, with a raised price target from $7 to $8.
The upgrade from Sell to Neutral indicates a more positive outlook on the company by UBS. The raised price target from $7 to $8 suggests that the analyst believes the stock has potential to increase in value. This could lead to increased investor confidence and potentially a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100